Summary
A total of 100 hospitalized patients with upper and lower urinary tract infections were treated with bacampicillin or ampicillin. The treatment was double-blind and 50 patients were randomly allocated to each group, receiving 800 mg of bacampicillin or 2 g of ampicillin t. i. d. for ten days. The distribution by age and sex was similar in the two groups. Assessments of therapeutic response and tolerance were made two and six weeks after initiation of therapy. In 89% of the patients treated with bacampicillin and 68% of the ampicillin-treated patients both the bacteria and the symptoms were eliminated at the first follow-up visit three days after end of therapy. Relapse or reinfection occurred in 44% of the ampicillin-treated patients as compared to 7% in the bacampicillin-treated patients. Side-effects occurred significantly less frequently with bacampicillin compared with ampicillin (p < 0.05). Treatment had to be stopped on account of side-effects in 16 patients treated with ampicillin compared with only four patients treated with bacampicillin.
Zusammenfassung
Insgesamt 100 Patienten mit Infektionen des oberen und unteren Harntrakts wurden mit Bacampicillin oder mit Ampicillin behandelt. Zur Doppelblind-Behandlung wurden jeweils 50 Patienten randomisiert zwei Gruppen zugeordnet, von denen die eine 800 mg Bacampicillin, die andere 2 g Ampicillin 3 x tgl. über zehn Tage erhielt. Die Verteilung von Alter und Geschlecht war in den beiden Gruppen ähnlich. Der Therapieerfolg und die Verträglichkeit wurden jeweils zwei und sechs Wochen nach Beginn der Behandlung beurteilt. Bei 89% der mit Bacampicillin und bei 68% der mit Ampicillin behandelten Patienten waren Bakterienelimination und Verschwinden der klinischen Symptome bei der ersten Verlaufsuntersuchung drei Tage nach Beendigung der Therapie festzustellen. Ein Rezidiv oder eine Reinfektion trat bei 44% der mit Ampicillin und bei 7% der mit Bacampicillin behandelten Patienten auf. Zu Nebenwirkungen kam es bei Bacampicillin signifikant seltener als bei Ampicillin (p < 0,05). Die Behandlung mußte bei 16 Patienten, die Ampicillin erhielten, verglichen mit nur vier Patienten, die Bacampicillin erhielten, unterbrochen werden.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literature
Simon, C. Antibiotikaspiegel in Serum-, Speichel-Tränen — und Hautblasenflüssigkeit. Infection 4 Suppl. 2 (1976) 91–96.
Rozencweig, M., Staquet, M., Klastersky, J. Antibacterial activity and pharmacokinetics of bacampicillin and ampicillin. Clin. Pharmacol. Ther. 19 (1976) 592–597.
Bodin, N.-O., Ekström, B., Forsgren, U., Jalar, L.-P., Magni, L., Ramsay, C.-H., Sjöberg, B. Bacampicillin, a new orally well-absorbed derivative of ampicillin. Antimicrob. Agents Chemother. 8 (1975) 518–525.
Hellum, K. B., Schreiner, A., Digranes, A., Bergmann, I. Skin blisters produced by suction: a new model for studies of penetration of antibiotics in humans. In:Siegenthaler, E., Lüthy, R. (eds): Current Chemotherapy I. American Society of Microbiology, Washington 1978, p. 620.
Raunio, V., Jokine, K., Karjalainen, S. Clinical bacteriological and pharmacological study of bacampicillin in chronic maxillary sinusitis — a comparison with ampicillin. In:Williams, J. O., Geddes, A. M. (eds): Chemotherapy Vol. 5, Penicillins and Cephalosporins. Plenum Press, New York 1976, p. 151.
Maesen, F. P. V., Buytendijk, H. J., Beeuwkes, H., Wessmann, J. A clinical and pharmacological comparison of bacampicillin and ampicillin in chronic bronchitis. 15th. Intersci. Conf. Antimicrob. Agents Chemother., Washington, 1975.
Magni, L., Sjövall, J., Syvälathi, E. Comparative clinical pharmacology of bacampicillin and high oral doses of ampicillin. Infection 8 (1978) 283–289.
Tuomaala, R. Bacampicillin and ampicillin in general practice: double-blind comparison in urinary tract infections. In:Siegenthaler, E., Lüthy, R. (eds). Current Chemotherapy I. American Society of Microbiology, Washington, 1978, p 207.
Hallander, H., Flodström, A., Sjövall, J. Pharmacological and clinical study of bacampicillin in acute peritonsillitis — a comparison with ampicillin. Antimicrob. Agents Chemother. 11 (1977) 185–190.
Olsson, O., Henning, C. Clinical study on bacampicillin in otitis media acuta and sinusitis acuta. In:Williams, J. O., Geddes, A. M. (eds): Chemotherapy Vol 5, Penicillins and Cephalosporins. Plenum Press, New York, 1976, p. 145.
Ekström, B., Forsgren, O., Magni, L., Sjöberg, B., Sjövall, J., Tolf, R. Bacampicillin, a well absorbed pro-drug of ampicillin — a report on properties and clinical experiences. Drug Res. 2 (1977) 39–44.
Brumfitt, W., Franklin, I., Hayek, L., Pursell, R. Treatment of urinary tract infection with pivampicillin. Scand. J. Infect. Dis. 5 (1973) 59–65.
Weuta, H. Das Ampicillin — Exanthem — Bericht über eine klinische Erfassungsaktion. Arzneim.-Forsch. 22 (1972) 1300–1306.
Ahlstedt, S., Kristofferson, A.: Experimental evidence of a decreased incidence of penicillin allergy through use of pure penicillin. Infection (1979), in press.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Müller-Ehrenberg, K.H., Müller, G. Bacampicillin and ampicillin in urinary tract infections: A double-blind comparison of efficacy and tolerance. Infection 7 (Suppl 5), S489–S491 (1979). https://doi.org/10.1007/BF01659780
Issue Date:
DOI: https://doi.org/10.1007/BF01659780